A Narrative Review of Tropisetron and Palonosetron for the Control of Chemotherapy-Induced Nausea and Vomiting

Yunpeng Yang; Li Zhang


Chin Clin Oncol. 2020;9(2):17 

In This Article


A literature search of EMBASE and PubMed was performed to identify publications reporting the results of tropisetron IV (generic forms or Navoban®) for the treatment of CINV in patients with various cancers. The search strings are detailed in Table 1; no publication date limits were applied. Table 2 details inclusion and exclusion criteria used to screen the publications

For palonosetron, only pivotal clinical studies evaluating the IV formulation of Aloxi® were included, because of the array of publications that have previously reviewed the use of palonosetron.

The doses considered in this review are tropisetron 5 mg IV and palonosetron 0.25 mg IV, both with and without dexamethasone (at variable doses).